Dynamic contrast-enhanced mri of malignant pleural mesothelioma: A feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome

Chest

Volumn 129, Issue 6, 2006, Pages 1570-1576

  Giesel, Frederik L ^a   Bischoff, Helge ^b   Von Tengg Kobligk, Hendrik ^a   Weber, Marc André ^a   Zechmann, Christian M ^a   Kauczor, Hans Ulrich ^a   Knopp, Michael V ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Thoraxklinik   (Germany)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Dynamic contrast enhanced MRI; Malignant pleural mesothelioma; Therapy monitoring

Indexed keywords

GADOLINIUM PENTETATE; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; DEVICE; DIFFERENTIAL DIAGNOSIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 33745137884     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1570     Document Type: Article

References (46)

1. Antman KH, Li FP, Pass HI, et al. Benign and malignant mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA: Lippincott, 1993; 1489-1508
2. Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E, Bast RC, et al, eds. Cancer medicine. 3rd ed. Philadelphia, PA: Lea & Febiger, 1993; 1337-1354
3. Ruffle P, Feld R, Minkin S, et al. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107(6 Suppl):332S-344S
4. Stewart DJ, Edwards JG, Smythe WR, et al. Malignant pleural mesothelioma: an update. Int J Occup Environ Health 2004; 10:26-39
5. Steinert DJ, Santos Dellea MM, Burger C, et al. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer 2005; 49(Suppl 1):S33-S35
6. Rusch VW, Godwin JD, Shuman WP, et al. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988; 96:171-177
7. Benard F, Sterman D. Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114:713-722
8. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8:1369-1375
9. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 2004; 45(suppl):S73-S76
10. Schneider DB, Clary-Macy C, Chalk S, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000; 129:128-133
11. Jeswani T, Padhani AR. Imaging tumor angiogenesis. Cancer Imaging 2005; 5:131-138
12. Lardinois D, Weder W, Many TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348:2500-2507
13. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003; 17:509-520
14. Hawighorst H, Knopp MV, Debus J, et al. Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging 1998; 8:783-788
15. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10:260-266
16. Hall GH, Atkin SL, Turnbull LW. Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries. J Reprod Med 2002; 47:107-114
17. Kroep JR, Peters GJ, van Moorsel CJ, et al. Gemcitabinecisplatin: a schedule finding study. Ann Oncol 1999; 10:1503-1510
18. Kayser K, Bohm G, Blum S, et al. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J Pathol 2001; 193:175-180
19. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976; 31:15-24
20. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991; 15:621-628
21. Hoffmann U, Brix G, Knopp MV, et al. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995; 33:506-514
22. Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345:535-539
23. Boutin C, Rey F, Gouvernet J. Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987. Bull Acad Natl Med 1992; 176:105-114
24. Butchart EG. Surgery of mesothelioma of the pleura. In: Roth JA, Ruckdeschel JC, Weinseinberger TH, eds. Thoracic oncology. Philadelphia, PA: W. B. Saunders, 1989; 566-583
25. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102:1-9
26. Mattson K, Holsti LR, Tammilehto L, et al. Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. Int J Radiat Oncol Biol Phys 1992; 24:643-650
27. Gordon W Jr, Antman KH, Greenberger JS, et al. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982; 8:19-25
28. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994; 38:212-214
29. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14:1007-1017
30. Hasturk S, Tastepe I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996; 8:159-164
31. Marom EM, Erasmus JJ, Pass HI, et al. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29:26-35
32. Knopp MV, Bischoff H, Lorenz WJ, et al. PET imaging of lung tumours and mediastinal lymphoma. Nucl Med Biol 1994; 21:749-757
33. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, et al. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003; 58:1077-1082
34. Detterbeck FC, Vansteenkiste JF, Morris DE, et al. Seeking a home for a PET, part 3: emerging applications of positron emission tomography imaging in the management of patients with lung cancer. Chest 2004; 126:1656-1666
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1976; 285:1182-1186
36. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995; 6:1059
37. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55:1189-1193
38. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor KDR, correlation with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968
39. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation m invasive breast carcinoma. N Engl J Med 1991; 324:1-8
40. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularisation to metastasis on non-small cell lung cancer. Lancet 1991; 340:145-146
41. Toi M, Hoshina S, Takayagani T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85:1045
42. Chodak GW, Haudenschild C, Gittes RF. Angiogenic activity as a marker of neoplasia and pre-neoplasia in lesions of the human bladder. Ann Surg 1980; 192:762-771
43. Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic factor in malignant mesothelioma. J Pathol 1997; 182:211-216
44. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81:54-61
45. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10:260-266
46. Kiessling F, Boese J, Corvinus C, et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization an treatment monitoring? Eur Radiol 2004; 14:1226-1233